Cancer biotech Ignyta files for a $40 million IPO


Shutterstock photo

Ignyta, a clinical-stage biotech developing targeted cancer therapeutics, filed on Friday with the SEC to raise up to $40 million in an initial public offering. The San Diego, CA-based company, which was founded in 2011, plans to list on the NASDAQ under the symbol RXDX. Ignyta is currently traded on the OTC market under the same ticker. Leerink Partners is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by